Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Immunogenicity of tumor-associated antigens (TAA) is often weak because many TAA are autoantigens for which the T-cell repertoire is sculpted by tolerance mechanisms. Substitutions at main anchor positions to increase the complementarity between the peptide and the MHC class I (MHC-I) binding cleft constitute a common procedure to improve binding capacity and immunogenicity of TAA. However, such alterations are tailored for each MHC-I allele and may recruit different CTL specificities through conformational changes in the targeted peptides. Comparative analysis of substituted melanoma-differentiation antigen gp100 in complex with H-2Db revealed that combined introduction of glycine and proline residues at the nonanchor positions 2 and 3, respectively, resulted in an agonistic altered peptide with dramatically enhanced binding affinity, stability, and immunogenicity of this TAA. Peptide vaccination using the p2Gp3P-altered peptide version of gp100 induced high frequencies of melanoma-specific CTL in the endogenous CD8+ repertoire. Crystal structure analysis of MHC/peptide complexes revealed that the conformation of the modified p2Gp3P-peptide was similar to the wild-type peptide, and indicated that this mimotope was stabilized through interactions between peptide residue p3P and the tyrosine residue Y159 that is conserved among most known MHC-I molecules throughout mammalian species. Our results may provide an alternative approach to enhance MHC stabilization capacity and immunogenicity of low-affinity peptides for induction of robust tumor-specific CTL. [Cancer Res 2009;69(19):7784–92]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Influence of proline residues on protein conformation
MacArthur, M. W., & Thornton, J. M. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90721-h · Cited by 1,189 · cited 1×
“The bulky pyrrolidine ring of the proline restricts the conformational freedom of the preceding residue (38), and although p2V is not unfavorable to binding of KVP, the positioning of the side chain of p2V will be constrained by sterical hindrances within the in the acidic B-pocket.”
BackgroundImmunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
Melief, C. J. M., & van der Burg, S. H. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2373 · Cited by 594
Cited by
Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy
Oberli, M. A., Reichmuth, A. M., Dorkin, J. R., Mitchell, M. J., Fenton, O. S., Jaklenec, A., Anderson, D. G., Langer, R., & Blankschtein, D. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b03329 · Cited by 719
Moynihan, K. D., Opel, C. F., Szeto, G. L., Tzeng, A., Zhu, E. F., Engreitz, J. M., Williams, R. T., Rakhra, K., Zhang, M. H., Rothschilds, A. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4200 · Cited by 524
CH–π hydrogen bonds in biological macromolecules
Nishio, M., Umezawa, Y., Fantini, J., Weiss, M. S., & Chakrabarti, P. (2014) · Phys. Chem. Chem. Phys. · doi:10.1039/c4cp00099d · Cited by 470
Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants
Hanson, M. C., Crespo, M. P., Abraham, W., Moynihan, K. D., Szeto, G. L., Chen, S. H., Melo, M. B., Mueller, S., & Irvine, D. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79915 · Cited by 381
Biomaterials for Nanoparticle Vaccine Delivery Systems
Sahdev, P., Ochyl, L. J., & Moon, J. J. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1419-y · Cited by 310
Metadata
- Authors
- van Stipdonk, M. J. B., Badia-Martinez, D., Sluijter, M., Offringa, R., van Hall, T., & Achour, A.
- Venue
- Cancer Research
- Published
- 2009-10-01
- Volume
- 69
- Issue
- 19
- Pages
- 7784-7792
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2131371327
- Cited by
- 91
- References
- 2
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100. https://app.cochat.ai/papers/10.1158/0008-5472.can-09-1724
- The paper
- van Stipdonk, M. J. B., Badia-Martinez, D., Sluijter, M., Offringa, R., van Hall, T., & Achour, A. (2009). Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100. Cancer Research. https://doi.org/10.1158/0008-5472.can-09-1724
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.